试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-30
Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)
编号:NCT05328102登记状态:提前终止企业 / 申办者:Xencor, Inc.
药物 / 成分:Plamotamab、Tafasitamab、Lenalidomide
登记的停止原因(原文):The study has been terminated early by the sponsor due to business decision.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-30
First-line Maintenance of OH2 Injection for Advanced Colorectal Cancer
编号:NCT05648006登记状态:提前终止企业 / 申办者:Binhui Biopharmaceutical Co., Ltd.
药物 / 成分:OH2、Capecitabine、Bevacizumab
登记的停止原因(原文):Strategy adjustment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-30
SGLT2 Inhibitors and Treatment of Heart Failure in Severe Renal Insufficiency
编号:NCT05737186登记状态:提前终止企业 / 申办者:Peking University People's Hospital
药物 / 成分:SGLT-2 inhibitor
登记的停止原因(原文):Double blind packaged drug is up to expiration date
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-29
Lithium for Suicidal Behavior in Mood Disorders
编号:NCT01928446登记状态:提前终止企业 / 申办者:VA Office of Research and Development
药物 / 成分:Lithium、Placebo
登记的停止原因(原文):terminated early due to non-safety related DMC recommendations
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-29
Study of KHK2823 in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
编号:NCT02181699登记状态:提前终止企业 / 申办者:Kyowa Kirin, Inc.
药物 / 成分:KHK2823
登记的停止原因(原文):Failed treatment response
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-29
The Effect of Two Aspirin Dosing Strategies for Obese Women at High Risk for Preeclampsia
编号:NCT03735433登记状态:提前终止企业 / 申办者:Ohio State University
药物 / 成分:162mg aspirin dose
登记的停止原因(原文):futility
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-26
Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer
编号:NCT00838578登记状态:提前终止企业 / 申办者:Kyowa Kirin Co., Ltd.
药物 / 成分:KRN330、Irinotecan
登记的停止原因(原文):Per protocol, the study was terminated based on interim analysis results
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-26
Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer
编号:NCT01279291登记状态:提前终止企业 / 申办者:Kyowa Kirin Co., Ltd.
药物 / 成分:KHK2866、Gemcitabine and Carboplatin、paclitaxel、pegylated liposomal doxorubicin
登记的停止原因(原文):The study was stopped due to the inability to determine an acceptable dose with the potential for further study
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-26
Alkotinib Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib
编号:NCT04211922登记状态:提前终止企业 / 申办者:Suzhou Zelgen Biopharmaceuticals Co.,Ltd
药物 / 成分:Alkotinib Capsules
登记的停止原因(原文):Sponsor R\&D Strategy Adjustment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-26
Nivolumab + Ipilimumab With Immunostimulatory Embolization for Stage 4 Renal Cell Carcinoma With Unresected Primary
编号:NCT04429321登记状态:提前终止企业 / 申办者:Abramson Cancer Center at Penn Medicine
药物 / 成分:Nivolumab、Ipilimumab、bland embolization
登记的停止原因(原文):failure to accrue
查看官方原始记录 ↗